1693-Chemotherapy Enhances Cancer Vaccine Efficacy

Research demonstrates that the chemotherapy combination CarboTaxol acts as a tumor-independent immunological adjuvant that significantly enhances the efficacy of therapeutic cancer vaccines. Specifically, the chemotherapy promotes an early expansion of stem-like TCF1+CD8+ T cells during vaccine priming, a process that relies heavily on downstream TCF1/β-catenin transcriptional activity. This expansion provides a crucial precursor reservoir that ultimately improves anti-tumor immunity, tumor control, and overall survival rates in murine models. Furthermore, human patient data from both ovarian and cervical cancer studies confirm a conserved, post-treatment increase in TCF1+CD8+ T cells. Building upon these mechanistic insights, adding anti-PD-1 checkpoint blockade creates a successful triple combination therapy that overcomes traditional timing restrictions and significantly enhances therapeutic outcomes.

References:

• Noblecourt L, Wicki A, Jainarayanan A, et al. Chemotherapy enhances cancer vaccine efficacy and expands stem-like TCF1+ CD8+ T cells[J]. Cancer Cell, 2026.